Substituted indian derivatives

Abstract

The present invention relates to new piperidyl- or piperazinyl-substituted indan derivatives of the formula I as (R)-enantiomers, (S)-enantiomers, or racemates in the form of a free base or pharmaceutically acceptable salts or solvates thereof. The present invention further relates to a process for the preparation of the compounds, to pharmaceutical compositions containing the compounds and to methods of treatment of 5-hydroxytryptamine-mediated disorders comprising administering the compounds.

1 . A compound having of the formula I  
       
         
           
           
               
               
           
         
       
       wherein 
 X is CH;  
 Y is NR 2 CH 2 , CH 2 NR 2 , NR 2 CO, CONR 2  or NR 2 SO 2  wherein R 2  is H or C 1 -C 6  alkyl;  
 R 1  is H, C 1 -C 6  alkyl or C 3 -C 6  cycloalkyl;  
 R 3  is C 1 -Cr alkyl, C 3 -C 6  cycloalkyl or (CH 2 ) n -aromatic ring,  
 wherein the aromatic ring is phenyl or a heteroaromatic ring containing one or two heteroatoms selected from the group consisting of N, O and S and wherein the aromatic ring may be mono- or di-substituted with R 4  and/or R 5 ; 
 wherein R 4  is H, C 1 -C 6  alkyl, C 3 -C 6  cycloalkyl, halogen, CN, CF 3 , OH, C 1 -C 6  alkoxy, NR 6 R 7 , OCF 3 , SO 3 CH 3 , SO 3 CF 3 , SO 2 NR 6 R 7 , phenyl, phenyl-C 1 -C 6  alkyl, phenoxy, C 1 -C 6  alkylphenyl, an optionally substituted heterocyclic ring containing one or two heteroatoms selected from the group consisting of N, O, S, SO and SO 2  wherein the substituent(s) is(are) selected from the group consisting of C 1 -C 6  alkyl C 3 -C 6  cycloalkyl and phenyl-C 1 -C 6  alkyl, an optionally substituted heteroaromatic ring containing one or two heteroatoms selected from the group consisting of N, O and S, wherein the substituent(s) is (are) selected from the group consisting of C 1 -C 6  alkyl, C 3 -C 6  cycloalkyl and phenyl-C 1 -C 6  alkyl, or COR 8 ; 
 wherein R 6  is H, C 1 -C 6  alkyl or C 3 -C 6  cycloalkyl;  
 R 7  is H, C 1 -C 6  alkyl or C 3 -C 6  cycloalkyl; and  
 R 8  is C 1 -C 6  alkyl, C 3 -C 6  cycloalkyl, CF 3 , NR 6 R 7 , phenyl, a heteroaromatic ring containing one or two heteroatoms selected from the group consisting of N, O and S, or a heterocyclic ring containing one or two heteroatoms selected from the group consisting of N, O, S, SO and SO 2 ;  
 
 wherein R 5  is H, OH, CF 3 , OCF 3 , halogen, C 1 -C 6  alkyl or C 1 -C 6  alkoxy;  
 n is 0-4;  
 
 R 9  is H, C 1 -C 6  alkyl, C 3 -C 6  cycloalkyl, OCF 3 , OCHF 2 , OCH 2 F, halogen, CN, CF 3 , OH, C 1 -C 6  alkoxy, C 1 -C 6  alkoxy-C 1 -C 6  alkyl, NR 6 R 7 , SO 3 CH 3 , SO 3 CF 3 , SO 2 NR 6 R 7 , an unsubstituted or substituted heterocyclic or heteroaromatic ring containing one or two heteroatoms selected from the group consisting of N, O and S, wherein the substituent(s) is(are) C 1 -C 6  alkyl; or COR 8 ; wherein R 6 , R 7  and R 8  are as defined above, wherein the compound is an (R)-enantiomer, an (S)-enantiomer, or a racemate in the form of a free base or a pharmaceutically acceptable salt or solvate thereof.  
 
     
     
         2 . The compound according to  claim 1  wherein Y is NR 2 CO or CONR 2 .  
     
     
         3 . (canceled)  
     
     
         4 . The compound according to  claim 1  wherein R 1  is H or C 1 -C 6  alkyl.  
     
     
         5 . The compound according  claim 1  wherein R 3  is (CH 2 ) n -aromatic ring.  
     
     
         6 . The compound according to  claim 5  wherein the aromatic ring of substituent R 3  is substituted with R 4 , and R 4  is an optionally substituted heterocyclic or heteroaromatic ring containing one or two heteroatoms selected from the group consisting of N, O and S; or COR 8 .  
     
     
         7 . The compound according to  claim 5  or  6  wherein n is 0.  
     
     
         8 . The compound according to  claim 6  wherein R 8  is NR 6 R 7  or a heterocyclic ring containing two heteroatoms selected from N and 0.  
     
     
         9 . The compound according to  claim 1  wherein R 9  is H, C 1 -C 6  alkyl, OCHF 2 , halogen or C 1 -C 6  alkoxy.  
     
     
         10 . The compound according to  claim 1  wherein Y is NR 2 CO and R 9  is C 1 -C 6  alkoxy.  
     
     
         11 . The compound according to  claim 10  wherein R 4  is morpholino or COR 8 .  
     
     
         12 . The compound according to  claim 1  wherein Y is NR 2 CO and R 9  is C 1 -C 6  alkyl.  
     
     
         13 . The compound according to  claim 12  wherein R 4  is morpholino or COR 8 .  
     
     
         14 . The compound according to  claim 1  wherein Y is NR 2 CO and R 9  is H.  
     
     
         15 . The compound according to  claim 14  wherein R 4  is morpholino or COR 8 .  
     
     
         16 . (canceled)  
     
     
         17 . A pharmaceutical formulation comprising as active ingredient a therapeutically effective amount of the compound of  claim 1 , wherein the compound is an enantiomer or racemate in the form of a free base or a pharmaceutically acceptable salt or solvate thereof optionally in association with diluents, excipients or inert carriers.  
     
     
         18 . A method for the treatment of 5-hydroxytryptamine-mediated disorders, comprising administering to a patient in need of such treatment a therapeutically effective amount of the pharmaceutical formulation of  claim 17 .  
     
     
         19 . A method for the treatment of mood disorders, anxiety disorders, personality disorders, obesity, anorexia, bulimia, premenstrual syndrome, sexual disturbances, alcoholism, tobacco abuse, autism, attention deficit, hyperactivity disorder, migraine, memory disorders, pathological aggression, schizophrenia, endocrine disorders, stroke, dyskinesia, Parkinson's disease, thermoregulatory disorders, pain, hypertension, urinary incontinence or vasospasm; or for inhibition of tumor growth, comprising administering to a patient in need of such treatment a therapeutically effective amount of the pharmaceutical formulation of  claim 17 .  
     
     
         20 . (canceled)  
     
     
         21 . A method for the treatment of 5-hydroxytryptamine-mediated disorders in the central nervous system, comprising administering to a patient in need of such treatment a therapeutically effective amount of the pharmaceutical formulation of  claim 17 .  
     
     
         22 - 29 . (canceled)  
     
     
         30 . A method for the treatment of 5-hydroxytryptamine-mediated disorders in the central nervous system and/or urinary incontinence or vasospasm, or for inhibition of tumor growth, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound defined in  claim 1 .  
     
     
         31 . The method according to  claim 30  for the treatment of mood disorders, anxiety disorders, personality disorders, obesity, anorexia, bulimia, premenstrual syndrome, sexual disturbances, alcoholism, tobacco abuse, autism, attention deficit, hyperactivity disorder, migraine, memory disorders, pathological aggression, schizophrenia, endocrine disorders, stroke, dyskinesia, Parkinson's disease, thermoregulatory disorders, pain or hypertension.  
     
     
         32 . (canceled)  
     
     
         33 . A method for the treatment of 5-hydroxytryptamine-mediated disorders which require treatment with an h5-HT 1B  antagonist, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound defined in  claim 1 .  
     
     
         34 . A process for the preparation of the compound of formula I according to  claim 1 , comprising reacting, in the case wherein Y is CONR 2  and R 1 , R 2 , R 3  and R 9  are as defined in  claim 1 , a compound of formula A  
       
         
           
           
               
               
           
         
       
       with a compound of formula VII, wherein X is a leaving group.  
     
     
         35 . (canceled)